Schering-Plough (SGP) Unveils Top-Line Results on SAPHRIS(TM) Showing Efficacy and Safety in Preventing Relapse of Schizophrenia; Reports Preladenant Met Primary Endpoints in Phase II Trial
Tweet Send to a Friend
Schering-Plough Corporation (NYSE: SGP) today revealed top-line results of a long-term Phase III clinical study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
